AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05161975 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin K2
Description: Volunteers will be randomly assigned to vitamin K2 or placebo group and consume one tablet of the food supplement per day.
Study NCT06438523 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: PULPOTOMY OF MATURE PERMENANT TEETH
Description: Removal of coronal pulp and expose the orifices to apply the materials with aim to preserve vitality of remaining pulp
Study NCT05799612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Given by IV (vein)
Study NCT05799612 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: mRNA plus Lysate-loaded Dendritic Cell Vaccine
Description: Given by IV (vein)
Study NCT05799612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEGYLATED-INTERFERON ALPHA-2A
Description: Given by IV (vein)
Study NCT05799612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Filgrastim
Description: Given by IV (vein)
Study NCT05918484 — intervention group
Intervention type: DEVICE
Intervention: Intermittenly scanned continuous glucose monitoring
Description: Use of Intermittenly scanned continuous glucose monitoring (FreeStyle Libre) and meeting the glycometric data criteria:~* Time in range 70-180 mg/L >70%~* Glycemic management index \<7%~* Coefficient of variation \<36%
Study NCT05918484 — intervention group
Intervention type: OTHER
Intervention: MODY genetic diagnostic test
Description: Those patients fulfilling the glycometric data criteria and with clinical MODY suspicion:~* diagnosis before 35 years of age~* first-degree family history of diabetes.~* negative pancreatic autoimmunity (Ac GAD, IA-2A and Ac ZnT8)~* preserved pancreatic beta cell function defined as C-peptide > 0.2 ng/mL in the presence of plasma glycemia >140 mg/dL).~Those patients who meet the previous criteria will proceed to the MODY genetic diagnostic test.
Study NCT04630236 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Ultrasound
Description: Using ultrasound control, the central vein catheter is injected with saline solution and the time to detect the saline bolus in the ultrasound is measured.
Study NCT06525025 — intervention group
Intervention type: OTHER
Intervention: Observational study, non intervention
Description: Observational study, non intervention
Study NCT06347861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single dose of vepdegestrant as tablet formulation (Treatment A)
Description: phase 3 tablets
Study NCT06347861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single dose of vepdegestrant as tablet formulation (Treatment B)
Description: registration tablets
Study NCT06347861 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: single dose of vepdegestrant as tablet formulation (Treatment C)
Description: registration tablets
Study NCT05045781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eptinezumab
Description: single iv infusion
Study NCT05032495 — intervention group
Intervention type: OTHER
Intervention: Surveys
Description: Surveys to evaluate prior experience, opinions and intervention acceptability.
Study NCT05032495 — intervention group
Intervention type: OTHER
Intervention: Focus group
Description: To answer any questions and discuss topics covered in the standard presentation.
Study NCT06056687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alpha Lipoic Acid 600 MG Oral Tablet
Description: Alpha Lipoic Acid 600 MG Oral Tablet once daily
Study NCT06056687 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Tablet
Description: Placebo Tablet once daily
Study NCT05321069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1015550
Description: BI 1015550
Study NCT05321069 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT06477146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Milk thistle (MT)
Description: MT capsules will contain 300 mg of MT with 80% content of Silymarin, standardized to 240mg Silymarin content. Dosing will be based on body weight with maximum dose of 600 mg/day. Dosing will be either 1 or 2 capsules per day based on weight.
Study NCT06477146 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo is consistent of Psyllium husk fiber, in 500mg per capsule composition.
Study NCT06477146 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Lifestyle Modification
Description: The primary instructions for lifestyle modification are:~1. Physical activity goal- 20-30 minutes per day 5 to 7 days per week. The aim is 150 minutes a week and more than 300 calories burnt for each workout.~2. Adequate hydration- 4-5 bottles of water a day.~3. Limitation of sugar-free beverages- once daily and 1-2 (8 oz) cups of skim/1% milk (or dairy alternative) daily.~4. Avoidance of beverages with added sugar such as soda, Kool-Aid, juice, and Gatorade.~5. Ideal consumption- three meals daily(breakfast, lunch, dinner)and one snack.~6. Snack Goal \<200 calories. If a 2nd, 3rd, etc. snack is desired it will only be a vegetable.~7. Five servings of fruits/vegetables per day.~8. Each food we recommend eating should have dietary fiber >3 grams/serving. Ideally >5 grams/serving.~9. The given survival guide will have all information regarding serving size and portion allotment.~10. MyPlate.gov handout given which will guide participants in relation to portion control.
Study NCT06477146 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fibroscan
Description: FibroScan will be completed to measure Elastography. Elastography works by emitting small pulse of energy which may be perceived as a vibration which quickly calculated the stiffness of the liver, which correlates to fat deposition and fibrosis.
Study NCT05173168 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic Dietary Supplement
Description: Probiotic dietary supplement containing 3 probiotic strains and 3 herbal extracts
Study NCT06204614 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable Micro-Device
Description: The implantable microdevice will release microdoses of specific drugs or drug combinations as a possible tool to evaluate the effectiveness of several cancer drugs against bladder cancer.
Study NCT05169515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC Mosunetuzumab
Description: Participants will receive SC mosunetuzumab for 12 cycles (cycle length = 21 days or 28 days for Cycle 1 and 28 days for Cycles 2-12)
Study NCT05169515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IV Glofitamab
Description: Participants will receive IV glofitamab for 12 cycles (cycle length = 21 days)
Study NCT05169515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Iberdomide
Description: Arm 1: Participants will receive oral CC-220 from Day 1-21 of Cycle 2-12 (cycle length = 28 days for Cycles 2-12)
Study NCT05169515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Golcadomide
Description: Arm 1: Participants will receive oral golcadomide from Day 1-14 starting in either Cycle 1 or Cycle 2 through Cycle 12 (cycle length = 28 days for cycles when golcadomide is to be administered) Arm 2: Participants will receive oral golcadomide from Day 1-10 starting in either Cycle 1, Cycle 2 or Cycle 3 through Cycle 12 (cycle length = 21 days)
Study NCT05169515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Participants in Arm 2 will receive pre-treatment with IV obinutuzumab on Cycle 1 Day 1 (cycle length = 21 days)
Study NCT05169515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: Participants will receive IV tocilizumab as needed to manage cytokine release syndrome (CRS)
Study NCT06135545 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Bupivacaine Liposome SAPB
Description: Dilute 266mg of bupivacaine liposome with saline solution to 30ml.The patients are placed in the lateral position and the probe is placed over the mid-clavicular region of the thoracic cage in a sagittal plane. The investigators count the ribs inferiorly and laterally, until The investigators identify the fifth rib in the midaxillary line. The latissimus dorsi (superficial and posterior), teres major (superior) and serratus muscles (deep and inferior) are then easily identifiable by ultrasound overlying the fifth rib.
Study NCT06135545 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Traditional TPVB
Description: The TPVB was recommended by the American Society of Anesthesiologists.The transducer is placed sagitally over a transverse process(TP), placing it at the center of the ultrasound image. Alternatively, the space in-between two adjacent transverse processes may be positioned at the center. The needle is inserted using an out-of-plane technique and advanced until the central TP is contacted, or else the cranial of the two, with no or minimal angulation in the sagittal plane or the transversal plane. Subsequently, the needle is walked off the TP into the TPV space and advanced 1 to 1.5 cm beyond the TP without further visualizing the needle tip on ultrasound. Entering of the needle tip into the TPV space can result in a loss of resistance to normal saline and by visualizing anterior displacement of the pleura upon injection. Select the fifth TP as the insertion point, and inject 20ml of 0.5% ropivacaine (Hengrui, Jiangsu) into the TPV space.
Study NCT06319820 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: TAR-210
Description: TAR-210 will be administered intravesically.
Study NCT06319820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: Gemcitabine will be administered intravesically.
Study NCT06319820 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: MMC
Description: MMC will be administered intravesically.
Study NCT05067348 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tocilizumab Injectable Product
Description: Participants will receive IV tocilizumab
Study NCT05067348 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab Injectable Product
Description: Participants will receive IV tocilizumab
Study NCT05870553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP0301-A
Description: Bowel Preparation
Study NCT05870553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP0301-B
Description: Bowel Preparation
Study NCT05870553 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cool prep
Description: Bowel Preparation
Study NCT06204614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Methotrexate will be placed in reservoir 1 of the implantable microdevice.
Study NCT06204614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin will be placed in reservoir 2 of the implantable microdevice.
Study NCT06204614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: Avelumab will be placed in reservoir 3 of the implantable microdevice.
Study NCT06204614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Paclitaxel will be placed in reservoir 4 of the implantable microdevice.
Study NCT06204614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: Vinblastine will be placed in reservoir 5 of the implantable microdevice.
Study NCT06204614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine/Cisplatin I
Description: Gemcitabine/Cisplatin will be placed in reservoir 6 of the implantable microdevice.
Study NCT06204614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate/Vinblastine/Doxorubicin/Cisplatin/Avelumab
Description: (Methotrexate/Vinblastine/Doxorubicin/Cisplatin/Avelumab) will be placed in reservoir 7 of the implantable microdevice.
Study NCT06204614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine/Cisplatin II
Description: Gemcitabine/Cisplatin will be placed in reservoir 8 of the implantable microdevice.
Study NCT06204614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Cisplatin will be placed in reservoir 9 of the implantable microdevice.
Study NCT06204614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab will be placed in reservoir 10 of the implantable microdevice.
Study NCT06204614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Pembrolizumab will be placed in reservoir 11 of the implantable microdevice.
Study NCT06204614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine/Carboplatin
Description: Gemcitabine/Carboplatin will be placed in reservoir 12 of the implantable microdevice.
Study NCT06204614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate/Vinblastine/Doxorubicin/Cisplatin
Description: (Methotrexate/Vinblastine/Doxorubicin/Cisplatin) will be placed in reservoir 13 of the implantable microdevice.
Study NCT06204614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine/Cisplatin/Nivolumab
Description: (Gemcitabine/Cisplatin/Nivolumab) will be placed in reservoir 14 of the implantable microdevice.
Study NCT06204614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Description: Erdafitinib will be placed in reservoir 15 of the implantable microdevice.
Study NCT06204614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel/Docetaxel/Ifosfamide
Description: (Paclitaxel/Docetaxel/Ifosfamide) will be placed in reservoir 16 of the implantable microdevice.
Study NCT06204471 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Helite hip protector
Description: hip protector
Study NCT05322850 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Orca-Q
Description: All transplant recipients enrolled on this study in both the phase I and phase II portions will receive Orca-Q (Orca-Q Prime and Orca-Q Supplement) intravenously following myeloablative conditioning.
Study NCT06204471 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wolk hip protector
Description: Hip protectdor
Study NCT06204614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine will be placed in reservoir 17 of the implantable microdevice.
Study NCT06204614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine/Carboplatin/Nivolumab
Description: (Gemcitabine/Carboplatin/Nivolumab) will be placed in reservoir 18 of the implantable microdevice.
Study NCT06204614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enfortumab
Description: Enfortumab will be placed in reservoir 19 of the implantable microdevice.
Study NCT06204614 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sacituzumab
Description: Sacitzumab will be placed in reservoir 20 of the implantable microdevice.
Study NCT05037357 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Plasma EBV DNA qPCR test
Description: Peripheral blood will be collected from each subject into an EDTA tube for the isolation of plasma.
Study NCT06657690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan liposome
Description: Irinotecan liposome injection, 50mg/m2, D1、D15, ivgtt, Q4w.
Study NCT06221800 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Microbiome
Description: Stool and saliva samples will be collected
Study NCT06657690 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S-1
Description: S-1, D1-D14, BID, p.o., Q4w (BSA \< 1.25 m2, 40 mg/dose; 1.25 m2 ⩽ BSA \< 1.5 m2, 50 mg/dose; BSA ⩾ 1.5 m2, 60mg/dose).
Study NCT06661460 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-Delivered Cognitive Behavioral Therapy
Description: The intervention is a therapist-guided, internet-delivered cognitive behavioral therapy (ICBT) program primarily based on exposure therapy, involving the gradual confrontation of feared situations and/or stimuli. Treatment is accessed through a smartphone, tablet or laptop/desktop device. The 12-week intervention is available in two different versions depending on the participant's age: one for 8-12-year-olds and one for 13-17-year-olds. Each version consists of separate logins to 12 modules (chapters) for the child/adolescent and 12 modules for the caregivers. Both the child/adolescent and caregiver have individual contact with a trained therapist over the internet platform. The therapist provides feedback, responds to questions and sends reminders to complete the next module if required. Communication is carried out via text messages in the platform, via telephone (if deemed justified) and through a scheduled telephone or videoconference call approximately 4-5 weeks into treatment.
Study NCT06659640 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ALN-6400
Description: ALN-6400 will be administered subcutaneously (SC)
Study NCT06659640 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be administered subcutaneously (SC)
Study NCT06662786 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Amivantamab will be administered.
Study NCT06662786 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Cetuximab will be administered.
Study NCT06662786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 5-fluorouracil will be administered as chemotherapy regimen.
Study NCT06662786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: 5-fluorouracil will be administered as chemotherapy regimen.
Study NCT06662786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin calcium/Levoleucovorin
Description: Leucovorin calcium/Levoleucovorin will be administered as chemotherapy regimen.
Study NCT06662786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Leucovorin calcium/Levoleucovorin
Description: Leucovorin calcium/Levoleucovorin will be administered as chemotherapy regimen.
Study NCT06662786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin will be administered as chemotherapy regimen.
Study NCT06662786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxaliplatin
Description: Oxaliplatin will be administered as chemotherapy regimen.
Study NCT06662786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Irinotecan hydrochloride will be administered as chemotherapy regimen.
Study NCT06662786 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Irinotecan Hydrochloride
Description: Irinotecan hydrochloride will be administered as chemotherapy regimen.
Study NCT06675162 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pilates Reformer Training
Description: Participants will perform a 60-minute Pilates Reformer muscle-strengthening session. The training will include a 7-10 minute warm-up, 35 minutes of muscle strengthening and mobility exercises and a 5-minute recovery. During the training, the physiological responses and the energy expenditure of the participants will be recorded.
Study NCT04743193 — intervention group
Intervention type: OTHER
Intervention: 2.5 %sevoflurane
Description: for 35 patients after reaching 1 MAK level with 4 lt / min fresh gas flow and 2,5% sevoflurane concentration in the initial phase, maintenance of anesthesia will be continued with 0.5 lt / min fresh gas flow and 2 -4% sevoflurane concentration with the target of 1 minimum alveolar concentration
Study NCT04743193 — intervention group
Intervention type: OTHER
Intervention: 8% sevoflurane low flow anesthesia
Description: For 35 patients after reaching 1 (MAC) level with 1 lt / min fresh gas flow and 8% sevoflurane concentration in the initial phase, maintenance of anesthesia will be continued with 0.5 lt / min fresh gas flow and 2 -4% sevoflurane concentration, targeting 1 MAC. .
Study NCT06625073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Description: A starting dose of empagliflozin 10 mg or matching placebo will be initiated after randomization and completion of the baseline testing. Participating subjects will remain at this dose for the whole study duration of 12 months.
Study NCT06625073 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A starting dose of empagliflozin 10 mg or matching placebo will be initiated after randomization and completion of the baseline testing. Participating subjects will remain at this dose for the whole study duration of 12 months.
Study NCT06624605 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Large Language Model-generated Plain Language Summary of Ophthalmology notes
Description: Prospective, randomized Quality Improvement study with real-world implementation of Large Language Model-generated Plain Language Summaries of Ophthalmology notes.
Study NCT05473663 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency Ablation
Description: Genicular nerve RFA is a standard outpatient procedure using fluoroscopic guidance to ensure accurate placement of the radiofrequency cannula. After placement of the radiofrequency cannula, nerve stimulation is performed to confirm proper position and ensure that the cannula is not too close to motor fibers. One mL of 2% lidocaine is placed at each of the cannulas. The RFA treatment is then proceeded by rhizotomizing each genicular nerve at 80°C for 90 seconds with a 15-second ramp-up.
Study NCT05473663 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham
Description: Is performed identically to the active treatment but without the application of the RFA current